
Amazon Up, Walgreens, Nike & McPlant Down
Motley Fool Money
00:00
The Disruption Dilemma: Weight Loss Drugs and Sleep Apnea Treatments
This chapter explores the effects of weight loss drugs like Eli Lilly's ZepBound on the medical technology sector, especially regarding sleep apnea treatments. It highlights the market fluctuation for ResMed and raises questions about the future of GLP-1 drugs in healthcare.
Play episode from 08:54
Transcript


